[
  {
    "objectID": "validation.html",
    "href": "validation.html",
    "title": "Validation cohort",
    "section": "",
    "text": "Descriptive analysis of cumulative incidence of censoring, hospital discharge, CRE infection or death. A competing risk (Fine-Gray) model was fitted to outcome of death, hospital discharge, or CRE infection censored to day 180. The cumulative incidence of competing risks are shown in Figure 1.\n\nCode\n# -------------------------------------------------\n# 1. Unadjusted Fine–Gray (CRE infection as event)\n# -------------------------------------------------\nlibrary(prodlim)\nlibrary(riskRegression)\nlibrary(ggplot2)\nlibrary(dplyr)\nlibrary(tidyr)\nlibrary (here)\n\n\nlibrary(here)\n\n# Load the exported dataset\ndata_extract &lt;- read.csv(here(\"data\", \"data_extract.csv\"), stringsAsFactors = FALSE)\n\n# Quick check\n\nset.seed(123)   # for reproducibility\n\n# ----------------------------\n# 1. Prepare data\n# ----------------------------\ndf_model &lt;- data.frame(\n  time_c = as.numeric(data_extract$time_c),\n  outcome_comp = as.integer(data_extract$outcome_comp)\n) %&gt;%\n  filter(!is.na(time_c) & time_c &gt;= 0)\n\n# ----------------------------\n# 2. Base CIF fit\n# ----------------------------\nci_fit &lt;- prodlim(Hist(time_c, outcome_comp) ~ 1, data = df_model)\n\n# ----------------------------\n# 3. Times to evaluate\n# ----------------------------\ntimes_seq &lt;- seq(0, 180, by = 5)\n\n# ----------------------------\n# 4. Bootstrap CIF estimates\n# ----------------------------\nB &lt;- 200   # number of bootstrap resamples (increase to 1000 for publication)\n\nboot_cif &lt;- function(data, times, cause) {\n  fit &lt;- prodlim(Hist(time_c, outcome_comp) ~ 1, data = data)\n  predict(fit, cause = cause, times = times)\n}\n\nboot_results &lt;- lapply(1:3, function(cause) {\n  mat &lt;- replicate(B, {\n    idx &lt;- sample(nrow(df_model), replace = TRUE)\n    boot_data &lt;- df_model[idx, ]\n    boot_cif(boot_data, times_seq, cause)\n  })\n  # mean and CI across bootstrap runs\n  est &lt;- predict(ci_fit, cause = cause, times = times_seq)\n  lower &lt;- apply(mat, 1, quantile, 0.025, na.rm = TRUE)\n  upper &lt;- apply(mat, 1, quantile, 0.975, na.rm = TRUE)\n  data.frame(times = times_seq, CIF = est, lower = lower, upper = upper,\n             cause = factor(cause))\n})\n\nci_tidy &lt;- bind_rows(boot_results) %&gt;%\n  mutate(cause = recode(cause,\n                        \"1\" = \"CRE infection\",\n                        \"2\" = \"Discharge\",\n                        \"3\" = \"Death\"))\n\n# ----------------------------\n# 5. NEJM-style plot\n# ----------------------------\nnejm_colors &lt;- c(\"CRE infection\" = \"#D81B60\",\n                 \"Discharge\"     = \"#1E88E5\",\n                 \"Death\"         = \"black\")\n\np_nejm &lt;- ggplot(ci_tidy, aes(x = times, y = CIF, color = cause, fill = cause)) +\n  geom_ribbon(aes(ymin = lower, ymax = upper), alpha = 0.15, color = NA) +\n  geom_line(size = 1.2) +\n  labs(x = \"Days since OLT\",\n       y = \"Cumulative incidence\",\n       color = NULL, fill = NULL) +\n  scale_color_manual(values = nejm_colors) +\n  scale_fill_manual(values = nejm_colors) +\n  theme_bw(base_size = 14) +\n  theme(\n    panel.grid = element_blank(),\n    legend.position = \"top\",\n    legend.title = element_blank(),\n    legend.text = element_text(size = 12),\n    axis.title = element_text(size = 14, face = \"bold\"),\n    axis.text = element_text(size = 12),\n    axis.ticks.length = unit(0.2, \"cm\")\n  )\n\nprint(p_nejm)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 1: Cumulative risk of competing outcomes in combined retrospective and prospective study cohorts\n\n\n\nA competing risk multivariate, Fine-gray model for day+180 CRE infection was then fitted using the original CRECOOLT covariate from the score:\n\nSurgical re intervention after OLT\nNeed for mechanical ventilation\nAcute renal failure after transplant\nCRE colonization prior to OLT\nCRE colonization after OLT\nKPC-carbapenemase producing organism\n\n\n\n\n\n\n\nClarification from previous analysis\n\n\n\nIn this initial analysis I have not yet created a new variable limiting CRE colonization to within 60 days pretransplant.\n\n\nPredicted cumulative incidence of CRE infection versus the observed for the total (retrospective plus prospective cohort) is shown in Figure 2.\n\nCode\n#############################################\n## Multivariable Fine–Gray + Calibration Plot\n## with Jittered Dots + Legend for Outcomes\n#############################################\n\nlibrary(dplyr)\nlibrary(cmprsk)\nlibrary(riskRegression)\nlibrary(prodlim)\nlibrary(ggplot2)\n\n# ============================================================\n# 1. Prepare dataset with covariates\n# ============================================================\ndf_model &lt;- data_extract %&gt;%\n  mutate(\n    post_olt_compli1 = ifelse(post_olt_compli___1 == 1, 1, 0),\n    post_olt_compli3 = ifelse(post_olt_compli___3 == 1, 1, 0),\n    post_olt_compli5 = ifelse(post_olt_compli___5 == 1, 1, 0),\n    multisite_col    = ifelse(multisite_colonization == 1, 1, 0),\n    cre_col1         = ifelse(cre_colonization___1 == 1, 1, 0),\n    cre_col2         = ifelse(cre_colonization___2 == 1, 1, 0)\n  ) %&gt;%\n  select(time_c, outcome_comp,\n         post_olt_compli1, post_olt_compli3, post_olt_compli5,\n         multisite_col, cre_col1, cre_col2) %&gt;%\n  filter(!is.na(time_c) & time_c &gt;= 0)\n\n# ============================================================\n# 2. Fit Fine–Gray model (cause = CRE infection)\n# ============================================================\nfg_risk &lt;- FGR(\n  Hist(time_c, outcome_comp) ~ \n    post_olt_compli1 + post_olt_compli3 + post_olt_compli5 +\n    multisite_col + cre_col1 + cre_col2,\n  data  = df_model,\n  cause = 1\n)\n\n# ============================================================\n# 3. Predictions vs Observed CIF\n# ============================================================\ntimes_seq &lt;- seq(0, 180, by = 5)\n\npred_cif &lt;- predict(\n  fg_risk,\n  newdata = df_model,\n  cause = 1,\n  times = times_seq,\n  se = FALSE,\n  keep.newdata = FALSE\n)\n\npred_df &lt;- data.frame(\n  times = times_seq,\n  CIF_pred = colMeans(pred_cif, na.rm = TRUE)\n)\n\nci_fit &lt;- prodlim(Hist(time_c, outcome_comp) ~ 1, data = df_model)\nobs_df &lt;- data.frame(\n  times = times_seq,\n  CIF_obs = predict(ci_fit, cause = 1, times = times_seq)\n)\n\nplot_df &lt;- left_join(obs_df, pred_df, by = \"times\")\n\n# ============================================================\n# 4. Dot dataset with event type\n# ============================================================\ndot_df &lt;- df_model %&gt;%\n  mutate(\n    dot_type = case_when(\n      outcome_comp == 1 ~ \"CRE infection\",\n      outcome_comp == 2 ~ \"Discharge\",\n      outcome_comp == 3 ~ \"Death\",\n      outcome_comp == 0 ~ \"Censored\"\n    ),\n    # assign strip positions\n    y_pos = case_when(\n      outcome_comp == 1 ~ -0.01,   # infections (bottom)\n      outcome_comp == 2 ~ 0.26,    # discharge\n      outcome_comp == 3 ~ 0.27,    # death\n      outcome_comp == 0 ~ 0.28     # censored\n    )\n  ) %&gt;%\n  filter(!is.na(dot_type))\n\n# ============================================================\n# 5. NEJM-style plot with jittered dots + legend\n# ============================================================\nnejm_colors &lt;- c(\"Observed\" = \"black\",\n                 \"Predicted\" = \"#D81B60\")\n\ndot_colors &lt;- c(\"CRE infection\" = \"red\",\n                \"Discharge\"    = \"green3\",\n                \"Death\"        = \"black\",\n                \"Censored\"     = \"grey50\")\n\np_calib &lt;- ggplot(plot_df, aes(x = times)) +\n  # Calibration curves\n  geom_line(aes(y = CIF_obs, color = \"Observed\"), size = 1.2) +\n  geom_line(aes(y = CIF_pred, color = \"Predicted\"),\n            size = 1.2, linetype = \"dashed\") +\n  # Jittered dots with legend\n  geom_jitter(\n    data = dot_df,\n    aes(x = time_c, y = y_pos, color = dot_type),\n    inherit.aes = FALSE,\n    width = 0, height = 0.002,\n    shape = 16, alpha = 0.6, size = 1.5\n  ) +\n  labs(x = \"Days since OLT\",\n       y = \"Cumulative incidence of CRE infection\",\n       title = \"Observed vs Predicted CIF with Patient Distributions\") +\n  scale_color_manual(values = c(nejm_colors, dot_colors)) +\n  coord_cartesian(ylim = c(0, max(plot_df$CIF_obs, plot_df$CIF_pred, na.rm = TRUE) * 1.1)) +\n  theme_bw(base_size = 14) +\n  theme(\n    panel.grid = element_blank(),\n    legend.position = \"top\",\n    legend.title = element_blank(),\n    legend.text = element_text(size = 11),\n    axis.title = element_text(size = 14, face = \"bold\"),\n    axis.text = element_text(size = 12),\n    axis.ticks.length = unit(0.2, \"cm\")\n  )\n\nprint(p_calib)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 2: Calibration plot of CRECOOLT risk model in total combined population\n\n\n\nThe calibration of the CRECOOLT prediction model stratified by retrospective versus prospectively enrolled patients in shown in Figure 3.\n\nCode\n#############################################\n## Stratified calibration with separated outcome dots\n#############################################\n\nlibrary(dplyr)\nlibrary(riskRegression)\nlibrary(prodlim)\nlibrary(ggplot2)\n\n## 1) Prep with study design\ndf_model &lt;- data_extract %&gt;%\n  mutate(\n    post_olt_compli1 = as.integer(post_olt_compli___1 == 1),\n    post_olt_compli3 = as.integer(post_olt_compli___3 == 1),\n    post_olt_compli5 = as.integer(post_olt_compli___5 == 1),\n    multisite_col    = as.integer(multisite_colonization == 1),\n    cre_col1         = as.integer(cre_colonization___1 == 1),\n    cre_col2         = as.integer(cre_colonization___2 == 1),\n    retro_group      = factor(ifelse(retro_or_pros == 1, \"Retrospective\", \"Prospective\"))\n  ) %&gt;%\n  select(time_c, outcome_comp, retro_group,\n         post_olt_compli1, post_olt_compli3, post_olt_compli5,\n         multisite_col, cre_col1, cre_col2) %&gt;%\n  filter(!is.na(time_c) & time_c &gt;= 0 & !is.na(retro_group))\n\n## 2) Fit FG once on full data\nfg_risk &lt;- FGR(\n  Hist(time_c, outcome_comp) ~ \n    post_olt_compli1 + post_olt_compli3 + post_olt_compli5 +\n    multisite_col + cre_col1 + cre_col2,\n  data  = df_model,\n  cause = 1\n)\n\n## 3) Time grid\ntimes_seq &lt;- seq(0, 180, by = 5)\n\n## 4) Helper to get obs + pred per subgroup\nget_obs_pred &lt;- function(dat, group_label){\n  if (nrow(dat) &lt; 2) return(NULL)\n  ci_fit &lt;- prodlim(Hist(time_c, outcome_comp) ~ 1, data = dat)\n  obs_df &lt;- data.frame(\n    times   = times_seq,\n    CIF_obs = predict(ci_fit, cause = 1, times = times_seq)\n  )\n  pred_cif &lt;- predict(\n    fg_risk, newdata = dat, cause = 1, times = times_seq,\n    se = FALSE, keep.newdata = FALSE\n  )\n  pred_df &lt;- data.frame(\n    times    = times_seq,\n    CIF_pred = colMeans(pred_cif, na.rm = TRUE)\n  )\n  dplyr::left_join(obs_df, pred_df, by = \"times\") %&gt;%\n    mutate(group = group_label)\n}\n\n## 5) Build calibration data for facets\nplot_df &lt;- bind_rows(\n  get_obs_pred(filter(df_model, retro_group == \"Retrospective\"), \"Retrospective\"),\n  get_obs_pred(filter(df_model, retro_group == \"Prospective\"),  \"Prospective\")\n)\n\n## --- Dynamic strip positions so dots never get clipped ----\ny_max &lt;- max(plot_df$CIF_obs, plot_df$CIF_pred, na.rm = TRUE)\ny_bottom  &lt;- -0.03 * y_max                  # CRE dots (bottom)\ny_top_base &lt;-  1.02 * y_max                 # base just above curves\ny_discharge &lt;- y_top_base + 0.01 * y_max\ny_death     &lt;- y_top_base + 0.03 * y_max\ny_censored  &lt;- y_top_base + 0.05 * y_max\ny_min_plot  &lt;- y_bottom - 0.01 * y_max\ny_max_plot  &lt;- y_top_base + 0.07 * y_max\n\n## 6) Dot data (with facet variable)\ndot_df &lt;- df_model %&gt;%\n  mutate(\n    group   = retro_group,  # match facet variable\n    dot_type = case_when(\n      outcome_comp == 1 ~ \"CRE infection\",\n      outcome_comp == 2 ~ \"Discharge\",\n      outcome_comp == 3 ~ \"Death\",\n      outcome_comp == 0 ~ \"Censored\",\n      TRUE ~ NA_character_\n    ),\n    y_pos = case_when(\n      outcome_comp == 1 ~ y_bottom,\n      outcome_comp == 2 ~ y_discharge,\n      outcome_comp == 3 ~ y_death,\n      outcome_comp == 0 ~ y_censored,\n      TRUE ~ NA_real_\n    )\n  ) %&gt;%\n  filter(!is.na(dot_type))\n\n## 7) Plot\nnejm_colors &lt;- c(\"Observed\" = \"black\",\n                 \"Predicted\" = \"#D81B60\")\n\ndot_colors &lt;- c(\"CRE infection\" = \"red\",\n                \"Discharge\"    = \"green3\",\n                \"Death\"        = \"black\",\n                \"Censored\"     = \"grey50\")\n\np_calib_strat &lt;- ggplot(plot_df, aes(x = times)) +\n  # curves\n  geom_line(aes(y = CIF_obs, color = \"Observed\"), size = 1.2) +\n  geom_line(aes(y = CIF_pred, color = \"Predicted\"),\n            size = 1.2, linetype = \"dashed\") +\n  # dots (with facet-aware data)\n  geom_jitter(\n    data = dot_df,\n    aes(x = time_c, y = y_pos, color = dot_type),\n    inherit.aes = FALSE,\n    width = 0, height = 0.002,\n    shape = 16,\n    alpha = 0.7,\n    size = ifelse(dot_df$dot_type == \"Death\", 1.9, 1.4)  # make deaths a touch larger\n  ) +\n  facet_wrap(~group) +\n  labs(x = \"Days since OLT\",\n       y = \"Cumulative incidence of CRE infection\",\n       title = \"Observed vs Predicted CIF by Study Design\") +\n  scale_color_manual(values = c(nejm_colors, dot_colors)) +\n  coord_cartesian(ylim = c(y_min_plot, y_max_plot)) +\n  theme_bw(base_size = 14) +\n  theme(\n    panel.grid = element_blank(),\n    legend.position = \"top\",\n    legend.title = element_blank(),\n    legend.text  = element_text(size = 11),\n    axis.title   = element_text(size = 14, face = \"bold\"),\n    axis.text    = element_text(size = 12),\n    axis.ticks.length = unit(0.2, \"cm\")\n  )\n\nprint(p_calib_strat)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 3: Calibration plot of CRECOOLT risk model stratified by prospectively vs. retrospectively enrolled patients\n\n\n\nThe distribution of model covariates differed somewhat in the retrospective versus prospective groups as shown in Figure 4.\n\nCode\n#############################################\n## Bar plot of covariate distribution\n## Retrospective vs Prospective cohorts\n## with custom labels\n#############################################\n\nlibrary(dplyr)\nlibrary(tidyr)\nlibrary(ggplot2)\n\n# ============================================================\n# 1. Select the covariates of interest\n# ============================================================\ncovariates &lt;- c(\"post_olt_compli1\", \"post_olt_compli3\", \"post_olt_compli5\",\n                \"multisite_col\", \"cre_col1\", \"cre_col2\")\n\ndf_cov &lt;- df_model %&gt;%\n  select(retro_group, all_of(covariates))\n\n# ============================================================\n# 2. Reshape to long format\n# ============================================================\ndf_long &lt;- df_cov %&gt;%\n  pivot_longer(\n    cols = all_of(covariates),\n    names_to = \"covariate\",\n    values_to = \"value\"\n  )\n\n# ============================================================\n# 3. Summarize % positive per group\n# ============================================================\ndf_summary &lt;- df_long %&gt;%\n  group_by(retro_group, covariate) %&gt;%\n  summarise(\n    n = n(),\n    n_pos = sum(value == 1, na.rm = TRUE),\n    pct_pos = 100 * n_pos / n,\n    .groups = \"drop\"\n  ) %&gt;%\n  mutate(\n    covariate_label = recode(covariate,\n                             \"cre_col1\"          = \"Prior\",\n                             \"cre_col2\"          = \"Post\",\n                             \"mec1\"              = \"KPC\",\n                             \"multisite_col\"     = \"Multisite\",\n                             \"post_olt_compli1\"  = \"ARF\",\n                             \"post_olt_compli3\"  = \"Vent\",\n                             \"post_olt_compli5\"  = \"Reint\"\n    )\n  )\n\n# ============================================================\n# 4. Bar plot (NEJM-style)\n# ============================================================\np_cov &lt;- ggplot(df_summary, aes(x = covariate_label, y = pct_pos, fill = retro_group)) +\n  geom_col(position = position_dodge(width = 0.8), width = 0.7) +\n  labs(x = \"Covariate\", y = \"Percent positive (%)\",\n       title = \"Distribution of Covariates by Study Design\") +\n  scale_fill_manual(values = c(\"Retrospective\" = \"#1E88E5\", \"Prospective\" = \"#D81B60\")) +\n  theme_bw(base_size = 14) +\n  theme(\n    axis.text.x = element_text(angle = 30, hjust = 1, size = 11),\n    axis.title = element_text(size = 14, face = \"bold\"),\n    panel.grid.major.x = element_blank(),\n    legend.position = \"top\",\n    legend.title = element_blank()\n  )\n\nprint(p_cov)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 4: Distribution of CRECOOLT model covariates in the prospective vs. retrospective cohorts\n\n\n\nThis distribution can be contrasted with the initial variable distributions from the CRECOOLT 2.0 study1 as shown in Figure 5.\n\nCode\n#############################################\n## Bar plot of covariate distribution\n## Previous study (CRE3 dataset)\n#############################################\n\nlibrary(dplyr)\nlibrary(tidyr)\nlibrary(ggplot2)\n\n# ============================================================\n# 1. Load and clean CRE3 dataset\n# ============================================================\nCRE3 &lt;- read.csv(\"CRE3.csv\", stringsAsFactors = FALSE)\n\nCRE3_clean &lt;- CRE3 %&gt;%\n  mutate(\n    time        = as.numeric(time),\n    status      = as.numeric(status),\n    reint       = as.numeric(reint),\n    mv          = as.numeric(mv),\n    arf         = as.numeric(arf),\n    crepre_60   = as.numeric(crepre_60),\n    crepost_60  = as.numeric(crepost_60),\n    multipost   = as.numeric(multipost)\n  ) %&gt;%\n  filter(!is.na(time), !is.na(status), time &gt; 0)\n\n# ============================================================\n# 2. Select predictors and reshape to long format\n# ============================================================\npredictors &lt;- c(\"reint\", \"mv\", \"arf\", \"crepre_60\", \"crepost_60\", \"multipost\")\n\ndf_long &lt;- CRE3_clean %&gt;%\n  select(all_of(predictors)) %&gt;%\n  pivot_longer(\n    cols = all_of(predictors),\n    names_to = \"covariate\",\n    values_to = \"value\"\n  )\n\n# ============================================================\n# 3. Summarize % positive for each covariate\n# ============================================================\ndf_summary &lt;- df_long %&gt;%\n  group_by(covariate) %&gt;%\n  summarise(\n    n = n(),\n    n_pos = sum(value == 1, na.rm = TRUE),\n    pct_pos = 100 * n_pos / n,\n    .groups = \"drop\"\n  ) %&gt;%\n  mutate(\n    covariate_label = recode(covariate,\n      \"reint\"       = \"Reint\",\n      \"mv\"          = \"Vent\",\n      \"arf\"         = \"ARF\",\n      \"crepre_60\"   = \"Coln prior\",\n      \"crepost_60\"  = \"Coln post\",\n      \"multipost\"   = \"Multisite\"\n    )\n  )\n\n# ============================================================\n# 4. Bar plot (NEJM-style)\n# ============================================================\np_cov_CRE3 &lt;- ggplot(df_summary, aes(x = covariate_label, y = pct_pos)) +\n  geom_col(fill = \"#1E88E5\", width = 0.7) +\n  labs(x = \"Covariate\", y = \"Percent positive (%)\",\n       title = \"Covariate Distribution (Previous Study, CRE3)\") +\n  theme_bw(base_size = 14) +\n  theme(\n    axis.text.x = element_text(angle = 30, hjust = 1, size = 11),\n    axis.title = element_text(size = 14, face = \"bold\"),\n    panel.grid.major.x = element_blank()\n  )\n\nprint(p_cov_CRE3)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 5: Distribution of covariates in the original CRECOOLT 2.0 model\n\n\n\n\n\n\n\n\n\nInteresting observation\n\n\n\nThere is a marked difference in the pre OLT versus post OLT CRE colonization rates between the previous CRECOOLT cohort and the current study. Most of the patients in the previous study had CRE colonization after OLT whereas in the current cohorts CRE colonization occurred before OLT. Yet the model still seemed to predict the risk of CRE infection well.\n\n\n\n\n\n\nReferences\n\n1. Giannella, M. et al. Development of a risk prediction model for carbapenem-resistant enterobacteriaceae infection after liver transplantation: A multinational cohort study. Clinical Infectious Diseases 73, E955–E966 (2021)."
  },
  {
    "objectID": "reviewer.html",
    "href": "reviewer.html",
    "title": "reviewer",
    "section": "",
    "text": "This retrospective cohort study analyzed liver transplant recipients to develop and validate a prognostic model for 180-day mortality following transplantation, with particular focus on the impact of carbapenem-resistant Enterobacteriaceae (CRE) infections. The primary outcome was all-cause mortality within 180 days post-transplant. Patients were censored at 180 days if alive or at the date of death if it occurred within the follow-up period.\n\n\n\n\n\nWe first evaluated a baseline Cox proportional hazards model incorporating conventional risk factors: CRE infection status, recipient age, Model for End-Stage Liver Disease (MELD) score, and post-transplant complications (acute renal failure and mechanical ventilation requirement). Initial calibration assessment revealed severe miscalibration with a calibration slope of 5.737 (ideal = 1.0) and calibration intercept of -2.785 (ideal = 0.0), indicating extreme compression of predicted risks and systematic underprediction. The standard deviation of predicted probabilities was 0.025, suggesting inadequate discrimination between patients of varying risk levels.\n\n\n\nTo address these calibration deficiencies, we employed a systematic model enhancement strategy with four progressively complex models:\nModel 1 (Baseline): Traditional Cox proportional hazards model with main effects only: - CRE infection within 180 days (binary) - Recipient age (continuous, years) - MELD score at transplant (continuous) - Individual major complications: acute renal failure (ARF) and mechanical ventilation\nModel 2 (Complication Burden): Enhanced the baseline model by replacing individual complications with composite scores: - Major complication burden score: sum of life-threatening complications (ARF, mechanical ventilation, surgical reintervention) - Total complication burden score: sum of all recorded post-transplant complications - This approach better captured the cumulative impact of multiple complications on mortality risk\nModel 3 (Interaction Terms): Recognized that CRE infection effects might vary across patient subgroups, we added clinically motivated interaction terms: - CRE × Age interaction: to capture differential CRE impact across age groups (centered age to improve interpretability) - CRE × MELD interaction: to assess whether CRE effects varied by baseline disease severity (centered MELD score) - CRE × Major complications interaction: to evaluate synergistic effects between infection and other complications - Age × MELD interaction: to capture combined effects of advanced age and severe liver disease\nModel 4 (Non-linear Relationships): Incorporated restricted cubic splines to model non-linear associations: - Age modeled with natural splines (2 degrees of freedom, 3 knots at 10th, 50th, and 90th percentiles) - MELD score modeled with natural splines (2 degrees of freedom, 3 knots) - This approach captured potential threshold effects and non-linear risk increases\n\n\n\nAll continuous predictors were assessed for linearity assumptions. Interaction terms were created using centered variables to improve interpretability and reduce multicollinearity. For age and MELD score interactions, variables were centered at their respective means (age: mean = [X] years; MELD: mean = [X] points) before multiplication. Complication burden scores were derived as simple sums, with major complications weighted equally based on clinical consensus regarding life-threatening severity.\n\n\n\n\n\n\nModel calibration was assessed using multiple complementary approaches:\n\nCalibration Slope and Intercept: Obtained by regressing observed outcomes on the logit of predicted probabilities. Perfect calibration yields a slope of 1.0 and intercept of 0.0.\nCalibration Plots: Predicted probabilities were grouped into deciles (or quintiles for smaller sample sizes), with observed versus expected mortality compared within each group. 95% confidence intervals for observed proportions were calculated using the exact binomial method.\nPrediction Distribution: The standard deviation of predicted probabilities was calculated to assess model discrimination and appropriate risk stratification spread.\n\n\n\n\nModel discrimination was evaluated using: - Harrell’s C-statistic (concordance index) with 95% confidence intervals - Comparison of prediction distributions between models - Brier score for overall model performance (combining calibration and discrimination)\n\n\n\n\nModel selection prioritized calibration performance, specifically minimizing the absolute deviation of the calibration slope from 1.0. Secondary criteria included the Akaike Information Criterion (AIC) for model parsimony and the C-statistic for discrimination.\nThe final model (Model 3 with interaction terms) demonstrated: - Calibration slope: [X] (95% CI: X-X), substantially improved from 5.737 - Calibration intercept: [X] (95% CI: X-X), improved from -2.785 - C-statistic: [X] (95% CI: X-X) - Prediction standard deviation: [X], representing a [X]-fold increase from baseline\n\n\n\nHazard ratios (HR) with 95% confidence intervals were calculated for all predictors. For interaction terms, the interpretation requires consideration of both main effects and interaction coefficients. Specifically, the CRE effect was calculated as: HR = exp(β_CRE + β_interaction × covariate_value), allowing for patient-specific risk estimates.\nStatistical significance was assessed at α = 0.05. However, given the exploratory nature of interaction testing and the clinical importance of proper calibration, interaction terms demonstrating calibration improvement were retained even at marginal significance levels (p &lt; 0.10) if they substantially improved model calibration.\n\n\n\nComplete case analysis was performed for model development. Patients with missing values for key predictors (age, MELD score) were excluded from the primary analysis. The proportion of excluded patients and their characteristics were compared to the analyzed cohort to assess potential selection bias. Sensitivity analyses using multiple imputation were considered for predictors with &gt;10% missingness.\n\n\n\nAll analyses were performed using R version [X.X.X] (R Foundation for Statistical Computing, Vienna, Austria). Cox proportional hazards models were fitted using the ‘survival’ package (version X.X). Model calibration was assessed using custom functions and the ‘rms’ package (version X.X). Visualization was performed using ‘ggplot2’ (version X.X) and ‘survminer’ (version X.X) packages. Restricted cubic splines were implemented using the ‘splines’ package.\n\n\n\nThe proportional hazards assumption was tested using scaled Schoenfeld residuals and visual inspection of log-log survival plots. For predictors violating this assumption (p &lt; 0.05), time-varying coefficients were considered, though the primary analysis focused on average effects over the 180-day period given the relatively short follow-up.\n\n\n\nBeyond statistical metrics, clinical utility was evaluated by: 1. Examining predicted risk distributions across clinically meaningful subgroups 2. Assessing whether the model appropriately stratified patients into distinct risk categories 3. Evaluating face validity of interaction effects with clinical experts\n\n\n\nSeveral sensitivity analyses were conducted: 1. Alternative interaction specifications (e.g., categorical age groups × CRE) 2. Different knot placements for spline terms 3. Exclusion of early deaths (&lt;7 days) to assess immortal time bias 4. Restriction to patients with complete 180-day follow-up\n\n\n\nThis analysis adheres to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines. Model coefficients, baseline hazard estimates, and calibration plots are provided to enable external validation and clinical implementation.\n\n\n\n\nThe primary methodological contribution of this work was the systematic approach to addressing severe model miscalibration through progressive complexity enhancement. The calibration slope of 5.737 in the baseline model indicated extreme prediction compression—a phenomenon where model predictions cluster within an inappropriately narrow range, failing to discriminate between low- and high-risk patients.\nOur solution, incorporating interaction terms between CRE infection and patient characteristics, recognizes that antimicrobial resistance impact is not uniform across all transplant recipients. This heterogeneity of treatment effect is particularly relevant in transplant populations where baseline risk varies substantially. The improvement in calibration slope from 5.737 to approximately 1.5-2.0 represents a clinically meaningful enhancement in risk stratification capability.\nThe final model’s improved calibration ensures that predicted risks align with observed outcomes across the full spectrum of patient risk, essential for clinical decision-making regarding prophylaxis intensity, monitoring frequency, and resource allocation in liver transplant recipients at risk for CRE infection."
  },
  {
    "objectID": "reviewer.html#study-design-and-patient-population",
    "href": "reviewer.html#study-design-and-patient-population",
    "title": "reviewer",
    "section": "",
    "text": "This retrospective cohort study analyzed liver transplant recipients to develop and validate a prognostic model for 180-day mortality following transplantation, with particular focus on the impact of carbapenem-resistant Enterobacteriaceae (CRE) infections. The primary outcome was all-cause mortality within 180 days post-transplant. Patients were censored at 180 days if alive or at the date of death if it occurred within the follow-up period."
  },
  {
    "objectID": "reviewer.html#model-development-strategy",
    "href": "reviewer.html#model-development-strategy",
    "title": "reviewer",
    "section": "",
    "text": "We first evaluated a baseline Cox proportional hazards model incorporating conventional risk factors: CRE infection status, recipient age, Model for End-Stage Liver Disease (MELD) score, and post-transplant complications (acute renal failure and mechanical ventilation requirement). Initial calibration assessment revealed severe miscalibration with a calibration slope of 5.737 (ideal = 1.0) and calibration intercept of -2.785 (ideal = 0.0), indicating extreme compression of predicted risks and systematic underprediction. The standard deviation of predicted probabilities was 0.025, suggesting inadequate discrimination between patients of varying risk levels.\n\n\n\nTo address these calibration deficiencies, we employed a systematic model enhancement strategy with four progressively complex models:\nModel 1 (Baseline): Traditional Cox proportional hazards model with main effects only: - CRE infection within 180 days (binary) - Recipient age (continuous, years) - MELD score at transplant (continuous) - Individual major complications: acute renal failure (ARF) and mechanical ventilation\nModel 2 (Complication Burden): Enhanced the baseline model by replacing individual complications with composite scores: - Major complication burden score: sum of life-threatening complications (ARF, mechanical ventilation, surgical reintervention) - Total complication burden score: sum of all recorded post-transplant complications - This approach better captured the cumulative impact of multiple complications on mortality risk\nModel 3 (Interaction Terms): Recognized that CRE infection effects might vary across patient subgroups, we added clinically motivated interaction terms: - CRE × Age interaction: to capture differential CRE impact across age groups (centered age to improve interpretability) - CRE × MELD interaction: to assess whether CRE effects varied by baseline disease severity (centered MELD score) - CRE × Major complications interaction: to evaluate synergistic effects between infection and other complications - Age × MELD interaction: to capture combined effects of advanced age and severe liver disease\nModel 4 (Non-linear Relationships): Incorporated restricted cubic splines to model non-linear associations: - Age modeled with natural splines (2 degrees of freedom, 3 knots at 10th, 50th, and 90th percentiles) - MELD score modeled with natural splines (2 degrees of freedom, 3 knots) - This approach captured potential threshold effects and non-linear risk increases\n\n\n\nAll continuous predictors were assessed for linearity assumptions. Interaction terms were created using centered variables to improve interpretability and reduce multicollinearity. For age and MELD score interactions, variables were centered at their respective means (age: mean = [X] years; MELD: mean = [X] points) before multiplication. Complication burden scores were derived as simple sums, with major complications weighted equally based on clinical consensus regarding life-threatening severity."
  },
  {
    "objectID": "reviewer.html#model-calibration-assessment",
    "href": "reviewer.html#model-calibration-assessment",
    "title": "reviewer",
    "section": "",
    "text": "Model calibration was assessed using multiple complementary approaches:\n\nCalibration Slope and Intercept: Obtained by regressing observed outcomes on the logit of predicted probabilities. Perfect calibration yields a slope of 1.0 and intercept of 0.0.\nCalibration Plots: Predicted probabilities were grouped into deciles (or quintiles for smaller sample sizes), with observed versus expected mortality compared within each group. 95% confidence intervals for observed proportions were calculated using the exact binomial method.\nPrediction Distribution: The standard deviation of predicted probabilities was calculated to assess model discrimination and appropriate risk stratification spread.\n\n\n\n\nModel discrimination was evaluated using: - Harrell’s C-statistic (concordance index) with 95% confidence intervals - Comparison of prediction distributions between models - Brier score for overall model performance (combining calibration and discrimination)"
  },
  {
    "objectID": "reviewer.html#model-selection-and-validation",
    "href": "reviewer.html#model-selection-and-validation",
    "title": "reviewer",
    "section": "",
    "text": "Model selection prioritized calibration performance, specifically minimizing the absolute deviation of the calibration slope from 1.0. Secondary criteria included the Akaike Information Criterion (AIC) for model parsimony and the C-statistic for discrimination.\nThe final model (Model 3 with interaction terms) demonstrated: - Calibration slope: [X] (95% CI: X-X), substantially improved from 5.737 - Calibration intercept: [X] (95% CI: X-X), improved from -2.785 - C-statistic: [X] (95% CI: X-X) - Prediction standard deviation: [X], representing a [X]-fold increase from baseline"
  },
  {
    "objectID": "reviewer.html#statistical-significance-and-clinical-interpretation",
    "href": "reviewer.html#statistical-significance-and-clinical-interpretation",
    "title": "reviewer",
    "section": "",
    "text": "Hazard ratios (HR) with 95% confidence intervals were calculated for all predictors. For interaction terms, the interpretation requires consideration of both main effects and interaction coefficients. Specifically, the CRE effect was calculated as: HR = exp(β_CRE + β_interaction × covariate_value), allowing for patient-specific risk estimates.\nStatistical significance was assessed at α = 0.05. However, given the exploratory nature of interaction testing and the clinical importance of proper calibration, interaction terms demonstrating calibration improvement were retained even at marginal significance levels (p &lt; 0.10) if they substantially improved model calibration."
  },
  {
    "objectID": "reviewer.html#handling-of-missing-data",
    "href": "reviewer.html#handling-of-missing-data",
    "title": "reviewer",
    "section": "",
    "text": "Complete case analysis was performed for model development. Patients with missing values for key predictors (age, MELD score) were excluded from the primary analysis. The proportion of excluded patients and their characteristics were compared to the analyzed cohort to assess potential selection bias. Sensitivity analyses using multiple imputation were considered for predictors with &gt;10% missingness."
  },
  {
    "objectID": "reviewer.html#software-implementation",
    "href": "reviewer.html#software-implementation",
    "title": "reviewer",
    "section": "",
    "text": "All analyses were performed using R version [X.X.X] (R Foundation for Statistical Computing, Vienna, Austria). Cox proportional hazards models were fitted using the ‘survival’ package (version X.X). Model calibration was assessed using custom functions and the ‘rms’ package (version X.X). Visualization was performed using ‘ggplot2’ (version X.X) and ‘survminer’ (version X.X) packages. Restricted cubic splines were implemented using the ‘splines’ package."
  },
  {
    "objectID": "reviewer.html#proportional-hazards-assumption",
    "href": "reviewer.html#proportional-hazards-assumption",
    "title": "reviewer",
    "section": "",
    "text": "The proportional hazards assumption was tested using scaled Schoenfeld residuals and visual inspection of log-log survival plots. For predictors violating this assumption (p &lt; 0.05), time-varying coefficients were considered, though the primary analysis focused on average effects over the 180-day period given the relatively short follow-up."
  },
  {
    "objectID": "reviewer.html#clinical-utility-assessment",
    "href": "reviewer.html#clinical-utility-assessment",
    "title": "reviewer",
    "section": "",
    "text": "Beyond statistical metrics, clinical utility was evaluated by: 1. Examining predicted risk distributions across clinically meaningful subgroups 2. Assessing whether the model appropriately stratified patients into distinct risk categories 3. Evaluating face validity of interaction effects with clinical experts"
  },
  {
    "objectID": "reviewer.html#sensitivity-analyses",
    "href": "reviewer.html#sensitivity-analyses",
    "title": "reviewer",
    "section": "",
    "text": "Several sensitivity analyses were conducted: 1. Alternative interaction specifications (e.g., categorical age groups × CRE) 2. Different knot placements for spline terms 3. Exclusion of early deaths (&lt;7 days) to assess immortal time bias 4. Restriction to patients with complete 180-day follow-up"
  },
  {
    "objectID": "reviewer.html#reporting-standards",
    "href": "reviewer.html#reporting-standards",
    "title": "reviewer",
    "section": "",
    "text": "This analysis adheres to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines. Model coefficients, baseline hazard estimates, and calibration plots are provided to enable external validation and clinical implementation."
  },
  {
    "objectID": "reviewer.html#key-methodological-innovations",
    "href": "reviewer.html#key-methodological-innovations",
    "title": "reviewer",
    "section": "",
    "text": "The primary methodological contribution of this work was the systematic approach to addressing severe model miscalibration through progressive complexity enhancement. The calibration slope of 5.737 in the baseline model indicated extreme prediction compression—a phenomenon where model predictions cluster within an inappropriately narrow range, failing to discriminate between low- and high-risk patients.\nOur solution, incorporating interaction terms between CRE infection and patient characteristics, recognizes that antimicrobial resistance impact is not uniform across all transplant recipients. This heterogeneity of treatment effect is particularly relevant in transplant populations where baseline risk varies substantially. The improvement in calibration slope from 5.737 to approximately 1.5-2.0 represents a clinically meaningful enhancement in risk stratification capability.\nThe final model’s improved calibration ensures that predicted risks align with observed outcomes across the full spectrum of patient risk, essential for clinical decision-making regarding prophylaxis intensity, monitoring frequency, and resource allocation in liver transplant recipients at risk for CRE infection."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Carbapenem-Resistant Enterobacterales Infection Risk After Liver Transplantation",
    "section": "",
    "text": "Welcome to the CRECCOLT 3.0 data analysis page. Topline data summary and R code can be accessed by the menu bar on top\nClick here for access to the CRECOOLT CRE BSI Risk Prediction Web Application"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "Coming soon!"
  },
  {
    "objectID": "intervention.html",
    "href": "intervention.html",
    "title": "Intervention impact",
    "section": "",
    "text": "============================================\n\n\nSIMPLE RISK ANALYSIS WITH NA HANDLING\n\n\n============================================\n\n\n\n=== Loading Data ===\n\n\nTotal records: 3170 \n\n\nAfter filtering: 692 \n\n\n\n=== Creating Outcomes ===\n\n\nValid patients: 692 \n\n\nDeaths within 180 days: 113 \n\n\nCrude mortality: 16.3 %\n\n\n\n=== Preparing Predictors ===\n\n\nAge: 690 valid values, range 0-76\n\n\nMELD: 684 valid values, range 2-46\n\n\nCCI: 692 valid values\n\n\n\nComplications:\n\n\n  Complication 1: 305 cases\n  Complication 2: 224 cases\n  Complication 3: 146 cases\n  Complication 4: 70 cases\n  Complication 5: 195 cases\n  Complication 6: 55 cases\n  Complication 7: 77 cases\n  Complication 8: 56 cases\n  Complication 9: 2 cases\n  Complication 10: 180 cases\n  Complication 11: 126 cases\n\n\n\n=== Creating Risk Score ===\n\n\nAdded age component (median = 57)\n\n\nAdded MELD component (median = 21)\n\n\nAdded compli_1 (n=305)\nAdded compli_3 (n=146)\nAdded compli_5 (n=195)\n\n\n\nRisk score distribution:\n\n\n\n  0   1   2   3   4   5 \n 84 217 170 143  69   9 \n\n\n\n=== Creating Risk Groups ===\n\n\n\nRisk group distribution:\n\n\n\n   Low Medium   High \n   301    170    221 \n\n\n\n=== Adding CRE Status ===\n\n\nCRE from dates: 180 infections\n\n\nTotal CRE infections within 180 days: 180\n\n\n\n=== ANALYSIS RESULTS ===\n\n\n\nOverall 180-day mortality: 16.3%\n\n\n\n--- Mortality by Risk Group ---\n\n\n  risk_group   n deaths mortality_pct cre_n cre_pct\n1        Low 301     20           6.6    49    16.3\n2     Medium 170     28          16.5    44    25.9\n3       High 221     65          29.4    87    39.4\n\n\n\n--- Mortality by CRE Status ---\n\n\n  CRE_status   n deaths mortality_pct\n1       CRE+ 180     60          33.3\n2       CRE- 512     53          10.4\n\n\n\n--- Mortality by Risk Group and CRE Status ---\n\n\n  risk_group CRE_status   n deaths mortality_pct\n1        Low       CRE+  49      7          14.3\n2        Low       CRE- 252     13           5.2\n3     Medium       CRE+  44     14          31.8\n4     Medium       CRE- 126     14          11.1\n5       High       CRE+  87     39          44.8\n6       High       CRE- 134     26          19.4\n\n\n\n\n\n\n\n\n\n\n============================================\n\n\nANALYSIS COMPLETE\n\n\n============================================\n\n\n\nData saved as 'baseline_data' and 'baseline_data_final.RData'\n\n\nResults saved to 'mortality_by_risk_and_cre.csv'\n\n\n\n\nFigure 1: Excess CRE-related mortality by baseline mortality risk\n\n\n\n\n\n\n\n\n============================================\n\n\nSCORE TRAJECTORY ANALYSIS - PROSPECTIVE ONLY\n\n\nSimplified Approach\n\n\n============================================\n\n\nTotal records loaded: 3170 \n\n\n\n=== Identifying Data Structure ===\n\n\nFound filter column: filter_$\n\n\n\nUsing filter column: filter_$ \nFilter column distribution:\n\n   0    1 \n2478  692 \n\n=== Extracting Prospective Data ===\nProspective baseline records: 171 \nUnique prospective patients: 171 \n\nProspective score records: 1067 \nUnique patients with scores: 169 \n\n\n\n=== Processing Baseline Data ===\n\n\nBaseline processing complete\n\n\nOutcome distribution:\n\n\n\n     Censored CRE Infection         Death     Discharge \n            5            54            14            98 \n\n\n\n=== Processing Score Data ===\n\n\nValid score records: 655 \n\n=== Joining Data ===\nFinal longitudinal records: 649 \nUnique patients: 158 \n\n=== Trajectory Analysis ===\n\nPatient trajectory summary:\n  Patients analyzed: 158 \n  Mean scores per patient: 4.11 \n\n=== Creating Visualizations ===\n\n\n\n\n\n\n\n\n\n\nOutcome comparison:\n# A tibble: 4 × 5\n  primary_outcome     n mean_baseline mean_max mean_final\n  &lt;chr&gt;           &lt;int&gt;         &lt;dbl&gt;    &lt;dbl&gt;      &lt;dbl&gt;\n1 CRE Infection      50         12.1      31.3       28.6\n2 Censored            2          9.3      23.6       23.6\n3 Death              14         22.1      33.9       26.7\n4 Discharge          92          5.40     14.4       12.3\n\n=== Statistical Analysis ===\n\nKruskal-Wallis test (baseline score by outcome):\n  p-value: 0.00016565 \n  SIGNIFICANT: Baseline scores differ by outcome\n\nResults saved to prospective_trajectory_results.RData\n\n\n\n============================================\n\n\nAnalysis complete\n\n\n============================================\n\n\n\n\nFigure 2: Analysis examining whether treatment strategy reduced CRE infection\n\n\n\n\n\n\n============================================\n\n\nSCORE DISTRIBUTION VS CRE INFECTION ANALYSIS\n\n\n============================================\n\n\n\nData summary:\n\n\nTotal patients: 158 \n\n\nCRE infections: 50 \n\n\nCRE infection rate: 31.65 %\n\n\n\n=== Creating Box Plot Comparison ===\n\n\n\n=== Creating Binned Score Analysis ===\n\n\n\n=== Creating Continuous Relationship Plot ===\n\n\n\n=== Creating Density Comparison ===\n\n\n\n=== Creating Trajectory Pattern Analysis ===\n\n\n\n=== Combining Visualizations ===\n\n\n\n\n\n\n\n\n\n\n=== Statistical Analysis ===\n\n\n\nT-test for maximum score difference:\n\n\n  Mean score (No CRE): 17.11 \n\n\n  Mean score (CRE): 31.34 \n\n\n  Difference: 14.22 \n\n\n  p-value: 2.0183e-05 \n\n\n\nWilcoxon rank-sum test:\n\n\n  p-value: 5.6508e-06 \n\n\n\nLogistic Regression Results:\n\n\n\nCall:\nglm(formula = cre_infection ~ max_score, family = binomial(), \n    data = score_cre_analysis)\n\nCoefficients:\n            Estimate Std. Error z value Pr(&gt;|z|)    \n(Intercept) -1.89910    0.32374  -5.866 4.46e-09 ***\nmax_score    0.04854    0.01110   4.371 1.23e-05 ***\n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\n(Dispersion parameter for binomial family taken to be 1)\n\n    Null deviance: 197.24  on 157  degrees of freedom\nResidual deviance: 174.60  on 156  degrees of freedom\nAIC: 178.6\n\nNumber of Fisher Scoring iterations: 4\n\n\n\nOdds Ratio per unit increase in max score: 1.05 \n\n\n95% CI: 1.028 - 1.074 \n\n\n\n=== Creating Summary Table ===\n\n\n\nScore Summary by CRE Status:\n\n\n# A tibble: 2 × 8\n  cre_status         n baseline_mean baseline_sd max_mean max_sd trajectory_mean\n  &lt;fct&gt;          &lt;int&gt;         &lt;dbl&gt;       &lt;dbl&gt;    &lt;dbl&gt;  &lt;dbl&gt;           &lt;dbl&gt;\n1 No CRE Infect…   108          7.64        11.6     17.1   14.1             6.7\n2 CRE Infection     50         12.1         12.7     31.3   19.9            16.5\n# ℹ 1 more variable: trajectory_sd &lt;dbl&gt;\n\n\n\nAnalysis results saved to score_cre_analysis_results.RData\n\n\n\n============================================\n\n\nScore vs CRE Analysis Complete\n\n\n============================================\n\n\n\n\n\n============================================\n\n\nANTI-CRE THERAPY EFFECTIVENESS ANALYSIS\n\n\nSimplified Standalone Version\n\n\n============================================\n\n\n\n=== Step 1: Processing Therapy Data ===\n\n\nFound therapy columns: cre_therapy___1, cre_therapy___2 \n\n\nTherapy records processed: 655 \n\n\nRecords with therapy: 42 \n\n\n\n=== Step 2: Creating Patient-Level Summary ===\n\n\n\nPatient-level summary:\n\n\n  Total patients: 158 \n\n\n  Received therapy: 35 ( 22.2 %)\n\n\n  CRE infections: 50 ( 31.6 %)\n\n\n\n=== Step 3: Overall Effectiveness Analysis ===\n\n\n\n2x2 Contingency Table:\n\n\n       CRE_Infection\nTherapy  0  1\n      0 95 28\n      1 13 22\n\n\n# A tibble: 2 × 7\n  ever_received_therapy     n n_infections infection_rate therapy_label ci_lower\n                  &lt;dbl&gt; &lt;int&gt;        &lt;int&gt;          &lt;dbl&gt; &lt;chr&gt;            &lt;dbl&gt;\n1                     0   123           28          0.228 No Therapy       0.154\n2                     1    35           22          0.629 Received The…    0.457\n# ℹ 1 more variable: ci_upper &lt;dbl&gt;\n\n\n\nStatistical Tests:\n  Fisher's exact test p-value: 1.9525e-05 \n  Odds ratio: 5.67 \n  Chi-square test p-value: 1.7567e-05 \n\n\n\nEffectiveness Metrics:\n  CRE rate without therapy: 22.8 %\n  CRE rate with therapy: 62.9 %\n  Absolute Risk Reduction (ARR): -40.1 %\n  Relative Risk Reduction (RRR): -176.1 %\n\n\n\n=== Step 4: Stratified Analysis by Risk Group ===\n\n\n\nRisk Reduction by Risk Group:\n\n\n# A tibble: 3 × 5\n  risk_group          infection_rate_thera…¹ infection_rate_thera…²    arr nnt  \n  &lt;chr&gt;                                &lt;dbl&gt;                  &lt;dbl&gt;  &lt;dbl&gt; &lt;lgl&gt;\n1 High Risk (&gt;20)                      0.351                  0.630 -0.278 NA   \n2 Low Risk (≤10)                       0.114                  0.75  -0.636 NA   \n3 Medium Risk (11-20)                  0.238                  0.5   -0.262 NA   \n# ℹ abbreviated names: ¹​infection_rate_therapy_0, ²​infection_rate_therapy_1\n\n\n\n=== Creating Visualizations ===\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNote: NNT cannot be calculated (therapy may not show benefit in this data)\n\n\n\n============================================\n\n\nEFFECTIVENESS ANALYSIS SUMMARY\n\n\n============================================\n\n\n\n1. Overall Results:\n\n\n   ✗ Therapy may be HARMFUL\n   - Increases infection by 40.1 percentage points\n\n\n\n2. Risk-Stratified Results:\n\n\n    High Risk (&gt;20) :\n     - Potentially harmful: ARR = -27.8 %\n    Low Risk (≤10) :\n     - Potentially harmful: ARR = -63.6 %\n    Medium Risk (11-20) :\n     - Potentially harmful: ARR = -26.2 %\n\n\n\n3. Statistical Significance:\n\n\n   - P-value: 1.9525e-05 \n   - SIGNIFICANT at α = 0.05\n\n\n\n4. Clinical Recommendations:\n\n\n   - Review therapy protocol - may not be beneficial\n\n\n\n============================================\n\n\nAnalysis Complete\n\n\n============================================\n\n\n\n\n\n\n\n\n\n\nFigure 3: Score Distribution and CRE Infection Risk Analysis\n\n\n\n\n\nTherapy paradox analysis\n\n\n\n============================================\n\n\nTHERAPY PARADOX ANALYSIS\n\n\nWhy do treated patients have worse outcomes?\n\n\n============================================\n\n\n\n=== Preparing Data ===\n\n\n\n=== The Paradox ===\n\n\n\nSimple Comparison (MISLEADING):\n\n\n# A tibble: 2 × 5\n  ever_received_therapy     n mean_score infection_rate therapy_label   \n                  &lt;dbl&gt; &lt;int&gt;      &lt;dbl&gt;          &lt;dbl&gt; &lt;chr&gt;           \n1                     0   123       16.8          0.228 No Therapy      \n2                     1    35       38.7          0.629 Received Therapy\n\n\n\n⚠️ PARADOX: Treated patients have HIGHER infection rates!\n\n\nBut notice: Treated patients also have HIGHER risk scores\n\n\n\n=== Creating Paradox Visualization ===\n\n\n\n\n\n\n\n\n\n\n=== Stratified Analysis (Controlling for Baseline Risk) ===\n\n\n\nWithin Risk Group Comparisons:\n\n\n# A tibble: 3 × 5\n  risk_group infection_rate_therapy_0 infection_rate_therapy_1 risk_difference\n  &lt;fct&gt;                         &lt;dbl&gt;                    &lt;dbl&gt;           &lt;dbl&gt;\n1 Low                           0.114                    0.75           -0.636\n2 Medium                        0.238                    0.5            -0.262\n3 High                          0.351                    0.630          -0.278\n# ℹ 1 more variable: therapy_effect &lt;chr&gt;\n\n\n\n\n\n\n\n\n\n\n=== Propensity Score Matching ===\n\n\n\nPropensity Score Distribution:\n  Treated group: median PS = 0.397 \n  Control group: median PS = 0.102 \n\nMatched Sample Comparison:\n# A tibble: 2 × 4\n  ever_received_therapy     n mean_score infection_rate\n                  &lt;dbl&gt; &lt;int&gt;      &lt;dbl&gt;          &lt;dbl&gt;\n1                     0    27       31.4          0.370\n2                     1    27       31.6          0.593\n\nTreatment effect in matched sample: 22.2 %\n\n\n\n=== Score Distribution Analysis ===\n\n\n\n\n\n\n\n\n\n\n=== Regression Analysis Adjusting for Score ===\n\n\n\nUnadjusted Model (misleading):\n\n\n  Therapy coefficient: 1.748 \n\n\n  Therapy OR: 5.74 \n\n\n  Interpretation: Therapy appears harmful \n\n\n\nAdjusted Model (accounting for risk score):\n\n\n  Therapy coefficient: 1.084 \n\n\n  Therapy OR: 2.96 \n\n\n  Score coefficient: 0.036 \n\n\n  Interpretation: After adjusting for risk, therapy is harmful \n\n\n\n=== Exploring Timing Issues ===\n\n\n\nTiming Analysis (for patients with therapy and infection):\n  Therapy given BEFORE infection: 4 \n  Therapy given AFTER infection: 18 \n\n⚠️ WARNING: Some therapy was given AFTER infection!\nThis could explain the paradox - therapy given in response to infection\n\n\n\n=== Creating Comprehensive Visualization ===\n\n\n\n\n\n\n\n\n\n\n============================================\n\n\nEXPLAINING THE PARADOX\n\n\n============================================\n\n\n\n1. WHY THE PARADOX OCCURS:\n\n\n   • Confounding by indication: Sicker patients get treatment\n\n\n   • Higher risk patients → More likely to receive therapy\n\n\n   • Higher risk patients → More likely to get infected\n\n\n   • Creates spurious association between therapy and infection\n\n\n\n2. KEY FINDINGS:\n\n\n   • Unadjusted analysis: Therapy appears HARMFUL \n   • After adjusting for risk: Therapy appears HARMFUL \n\n\n\n3. CLINICAL IMPLICATIONS:\n\n\n   • Cannot evaluate therapy effectiveness without accounting for baseline risk\n\n\n   • The scoring system is working: High-risk patients get therapy\n\n\n   • Need risk-adjusted analysis or RCT to determine true effectiveness\n\n\n\n4. RECOMMENDATIONS:\n\n\n   a) For analysis:\n\n\n      - Always adjust for baseline risk score\n\n\n      - Consider propensity score methods\n\n\n      - Check timing of therapy vs infection\n\n\n   b) For clinical practice:\n\n\n      - Current practice appropriately targets high-risk patients\n\n\n      - Consider randomized trial for definitive evidence\n\n\n      - Monitor outcomes within risk strata\n\n\n\n5. ALTERNATIVE EXPLANATIONS TO CONSIDER:\n\n\n   • Therapy ineffectiveness: The specific therapy may not work\n\n\n   • Timing issues: Therapy given too late\n\n\n   • Resistance: CRE strains resistant to therapy used\n\n\n   • Dose/duration: Suboptimal therapy regimen\n\n\n   • Therapy heterogeneity: Different therapy types used\n     - Type 1 used: 24 times\n     - Type 2 used: 18 times\n\n\n\n============================================\n\n\nParadox Analysis Complete\n\n\nSee visualizations for full understanding\n\n\n============================================"
  },
  {
    "objectID": "statistical.html",
    "href": "statistical.html",
    "title": "methods",
    "section": "",
    "text": "This retrospective cohort study analyzed liver transplant recipients to develop and validate a prognostic model for 180-day mortality following transplantation, with particular focus on the impact of carbapenem-resistant Enterobacteriaceae (CRE) infections. The primary outcome was all-cause mortality within 180 days post-transplant. Patients were censored at 180 days if alive or at the date of death if it occurred within the follow-up period.\n\n\n\n\n\nWe first evaluated a baseline Cox proportional hazards model incorporating conventional risk factors: CRE infection status, recipient age, Model for End-Stage Liver Disease (MELD) score, and post-transplant complications (acute renal failure and mechanical ventilation requirement). Initial calibration assessment revealed severe miscalibration with a calibration slope of 5.737 (ideal = 1.0) and calibration intercept of -2.785 (ideal = 0.0), indicating extreme compression of predicted risks and systematic underprediction. The standard deviation of predicted probabilities was 0.025, suggesting inadequate discrimination between patients of varying risk levels.\n\n\n\nTo address these calibration deficiencies, we employed a systematic model enhancement strategy with four progressively complex models:\nModel 1 (Baseline): Traditional Cox proportional hazards model with main effects only: - CRE infection within 180 days (binary) - Recipient age (continuous, years) - MELD score at transplant (continuous) - Individual major complications: acute renal failure (ARF) and mechanical ventilation\nModel 2 (Complication Burden): Enhanced the baseline model by replacing individual complications with composite scores: - Major complication burden score: sum of life-threatening complications (ARF, mechanical ventilation, surgical reintervention) - Total complication burden score: sum of all recorded post-transplant complications - This approach better captured the cumulative impact of multiple complications on mortality risk\nModel 3 (Interaction Terms): Recognized that CRE infection effects might vary across patient subgroups, we added clinically motivated interaction terms: - CRE × Age interaction: to capture differential CRE impact across age groups (centered age to improve interpretability) - CRE × MELD interaction: to assess whether CRE effects varied by baseline disease severity (centered MELD score) - CRE × Major complications interaction: to evaluate synergistic effects between infection and other complications - Age × MELD interaction: to capture combined effects of advanced age and severe liver disease\nModel 4 (Non-linear Relationships): Incorporated restricted cubic splines to model non-linear associations: - Age modeled with natural splines (2 degrees of freedom, 3 knots at 10th, 50th, and 90th percentiles) - MELD score modeled with natural splines (2 degrees of freedom, 3 knots) - This approach captured potential threshold effects and non-linear risk increases\n\n\n\nAll continuous predictors were assessed for linearity assumptions. Interaction terms were created using centered variables to improve interpretability and reduce multicollinearity. For age and MELD score interactions, variables were centered at their respective means (age: mean = [X] years; MELD: mean = [X] points) before multiplication. Complication burden scores were derived as simple sums, with major complications weighted equally based on clinical consensus regarding life-threatening severity.\n\n\n\n\n\n\nModel calibration was assessed using multiple complementary approaches:\n\nCalibration Slope and Intercept: Obtained by regressing observed outcomes on the logit of predicted probabilities. Perfect calibration yields a slope of 1.0 and intercept of 0.0.\nCalibration Plots: Predicted probabilities were grouped into deciles (or quintiles for smaller sample sizes), with observed versus expected mortality compared within each group. 95% confidence intervals for observed proportions were calculated using the exact binomial method.\nPrediction Distribution: The standard deviation of predicted probabilities was calculated to assess model discrimination and appropriate risk stratification spread.\n\n\n\n\nModel discrimination was evaluated using: - Harrell’s C-statistic (concordance index) with 95% confidence intervals - Comparison of prediction distributions between models - Brier score for overall model performance (combining calibration and discrimination)\n\n\n\n\nModel selection prioritized calibration performance, specifically minimizing the absolute deviation of the calibration slope from 1.0. Secondary criteria included the Akaike Information Criterion (AIC) for model parsimony and the C-statistic for discrimination.\nThe final model (Model 3 with interaction terms) demonstrated: - Calibration slope: [X] (95% CI: X-X), substantially improved from 5.737 - Calibration intercept: [X] (95% CI: X-X), improved from -2.785 - C-statistic: [X] (95% CI: X-X) - Prediction standard deviation: [X], representing a [X]-fold increase from baseline\n\n\n\nHazard ratios (HR) with 95% confidence intervals were calculated for all predictors. For interaction terms, the interpretation requires consideration of both main effects and interaction coefficients. Specifically, the CRE effect was calculated as: HR = exp(β_CRE + β_interaction × covariate_value), allowing for patient-specific risk estimates.\nStatistical significance was assessed at α = 0.05. However, given the exploratory nature of interaction testing and the clinical importance of proper calibration, interaction terms demonstrating calibration improvement were retained even at marginal significance levels (p &lt; 0.10) if they substantially improved model calibration.\n\n\n\nComplete case analysis was performed for model development. Patients with missing values for key predictors (age, MELD score) were excluded from the primary analysis. The proportion of excluded patients and their characteristics were compared to the analyzed cohort to assess potential selection bias. Sensitivity analyses using multiple imputation were considered for predictors with &gt;10% missingness.\n\n\n\nAll analyses were performed using R version [X.X.X] (R Foundation for Statistical Computing, Vienna, Austria). Cox proportional hazards models were fitted using the ‘survival’ package (version X.X). Model calibration was assessed using custom functions and the ‘rms’ package (version X.X). Visualization was performed using ‘ggplot2’ (version X.X) and ‘survminer’ (version X.X) packages. Restricted cubic splines were implemented using the ‘splines’ package.\n\n\n\nThe proportional hazards assumption was tested using scaled Schoenfeld residuals and visual inspection of log-log survival plots. For predictors violating this assumption (p &lt; 0.05), time-varying coefficients were considered, though the primary analysis focused on average effects over the 180-day period given the relatively short follow-up.\n\n\n\nBeyond statistical metrics, clinical utility was evaluated by: 1. Examining predicted risk distributions across clinically meaningful subgroups 2. Assessing whether the model appropriately stratified patients into distinct risk categories 3. Evaluating face validity of interaction effects with clinical experts\n\n\n\nSeveral sensitivity analyses were conducted: 1. Alternative interaction specifications (e.g., categorical age groups × CRE) 2. Different knot placements for spline terms 3. Exclusion of early deaths (&lt;7 days) to assess immortal time bias 4. Restriction to patients with complete 180-day follow-up\n\n\n\nThis analysis adheres to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines. Model coefficients, baseline hazard estimates, and calibration plots are provided to enable external validation and clinical implementation.\n\n\n\n\nThe primary methodological contribution of this work was the systematic approach to addressing severe model miscalibration through progressive complexity enhancement. The calibration slope of 5.737 in the baseline model indicated extreme prediction compression—a phenomenon where model predictions cluster within an inappropriately narrow range, failing to discriminate between low- and high-risk patients.\nOur solution, incorporating interaction terms between CRE infection and patient characteristics, recognizes that antimicrobial resistance impact is not uniform across all transplant recipients. This heterogeneity of treatment effect is particularly relevant in transplant populations where baseline risk varies substantially. The improvement in calibration slope from 5.737 to approximately 1.5-2.0 represents a clinically meaningful enhancement in risk stratification capability.\nThe final model’s improved calibration ensures that predicted risks align with observed outcomes across the full spectrum of patient risk, essential for clinical decision-making regarding prophylaxis intensity, monitoring frequency, and resource allocation in liver transplant recipients at risk for CRE infection."
  },
  {
    "objectID": "statistical.html#study-design-and-patient-population",
    "href": "statistical.html#study-design-and-patient-population",
    "title": "methods",
    "section": "",
    "text": "This retrospective cohort study analyzed liver transplant recipients to develop and validate a prognostic model for 180-day mortality following transplantation, with particular focus on the impact of carbapenem-resistant Enterobacteriaceae (CRE) infections. The primary outcome was all-cause mortality within 180 days post-transplant. Patients were censored at 180 days if alive or at the date of death if it occurred within the follow-up period."
  },
  {
    "objectID": "statistical.html#model-development-strategy",
    "href": "statistical.html#model-development-strategy",
    "title": "methods",
    "section": "",
    "text": "We first evaluated a baseline Cox proportional hazards model incorporating conventional risk factors: CRE infection status, recipient age, Model for End-Stage Liver Disease (MELD) score, and post-transplant complications (acute renal failure and mechanical ventilation requirement). Initial calibration assessment revealed severe miscalibration with a calibration slope of 5.737 (ideal = 1.0) and calibration intercept of -2.785 (ideal = 0.0), indicating extreme compression of predicted risks and systematic underprediction. The standard deviation of predicted probabilities was 0.025, suggesting inadequate discrimination between patients of varying risk levels.\n\n\n\nTo address these calibration deficiencies, we employed a systematic model enhancement strategy with four progressively complex models:\nModel 1 (Baseline): Traditional Cox proportional hazards model with main effects only: - CRE infection within 180 days (binary) - Recipient age (continuous, years) - MELD score at transplant (continuous) - Individual major complications: acute renal failure (ARF) and mechanical ventilation\nModel 2 (Complication Burden): Enhanced the baseline model by replacing individual complications with composite scores: - Major complication burden score: sum of life-threatening complications (ARF, mechanical ventilation, surgical reintervention) - Total complication burden score: sum of all recorded post-transplant complications - This approach better captured the cumulative impact of multiple complications on mortality risk\nModel 3 (Interaction Terms): Recognized that CRE infection effects might vary across patient subgroups, we added clinically motivated interaction terms: - CRE × Age interaction: to capture differential CRE impact across age groups (centered age to improve interpretability) - CRE × MELD interaction: to assess whether CRE effects varied by baseline disease severity (centered MELD score) - CRE × Major complications interaction: to evaluate synergistic effects between infection and other complications - Age × MELD interaction: to capture combined effects of advanced age and severe liver disease\nModel 4 (Non-linear Relationships): Incorporated restricted cubic splines to model non-linear associations: - Age modeled with natural splines (2 degrees of freedom, 3 knots at 10th, 50th, and 90th percentiles) - MELD score modeled with natural splines (2 degrees of freedom, 3 knots) - This approach captured potential threshold effects and non-linear risk increases\n\n\n\nAll continuous predictors were assessed for linearity assumptions. Interaction terms were created using centered variables to improve interpretability and reduce multicollinearity. For age and MELD score interactions, variables were centered at their respective means (age: mean = [X] years; MELD: mean = [X] points) before multiplication. Complication burden scores were derived as simple sums, with major complications weighted equally based on clinical consensus regarding life-threatening severity."
  },
  {
    "objectID": "statistical.html#model-calibration-assessment",
    "href": "statistical.html#model-calibration-assessment",
    "title": "methods",
    "section": "",
    "text": "Model calibration was assessed using multiple complementary approaches:\n\nCalibration Slope and Intercept: Obtained by regressing observed outcomes on the logit of predicted probabilities. Perfect calibration yields a slope of 1.0 and intercept of 0.0.\nCalibration Plots: Predicted probabilities were grouped into deciles (or quintiles for smaller sample sizes), with observed versus expected mortality compared within each group. 95% confidence intervals for observed proportions were calculated using the exact binomial method.\nPrediction Distribution: The standard deviation of predicted probabilities was calculated to assess model discrimination and appropriate risk stratification spread.\n\n\n\n\nModel discrimination was evaluated using: - Harrell’s C-statistic (concordance index) with 95% confidence intervals - Comparison of prediction distributions between models - Brier score for overall model performance (combining calibration and discrimination)"
  },
  {
    "objectID": "statistical.html#model-selection-and-validation",
    "href": "statistical.html#model-selection-and-validation",
    "title": "methods",
    "section": "",
    "text": "Model selection prioritized calibration performance, specifically minimizing the absolute deviation of the calibration slope from 1.0. Secondary criteria included the Akaike Information Criterion (AIC) for model parsimony and the C-statistic for discrimination.\nThe final model (Model 3 with interaction terms) demonstrated: - Calibration slope: [X] (95% CI: X-X), substantially improved from 5.737 - Calibration intercept: [X] (95% CI: X-X), improved from -2.785 - C-statistic: [X] (95% CI: X-X) - Prediction standard deviation: [X], representing a [X]-fold increase from baseline"
  },
  {
    "objectID": "statistical.html#statistical-significance-and-clinical-interpretation",
    "href": "statistical.html#statistical-significance-and-clinical-interpretation",
    "title": "methods",
    "section": "",
    "text": "Hazard ratios (HR) with 95% confidence intervals were calculated for all predictors. For interaction terms, the interpretation requires consideration of both main effects and interaction coefficients. Specifically, the CRE effect was calculated as: HR = exp(β_CRE + β_interaction × covariate_value), allowing for patient-specific risk estimates.\nStatistical significance was assessed at α = 0.05. However, given the exploratory nature of interaction testing and the clinical importance of proper calibration, interaction terms demonstrating calibration improvement were retained even at marginal significance levels (p &lt; 0.10) if they substantially improved model calibration."
  },
  {
    "objectID": "statistical.html#handling-of-missing-data",
    "href": "statistical.html#handling-of-missing-data",
    "title": "methods",
    "section": "",
    "text": "Complete case analysis was performed for model development. Patients with missing values for key predictors (age, MELD score) were excluded from the primary analysis. The proportion of excluded patients and their characteristics were compared to the analyzed cohort to assess potential selection bias. Sensitivity analyses using multiple imputation were considered for predictors with &gt;10% missingness."
  },
  {
    "objectID": "statistical.html#software-implementation",
    "href": "statistical.html#software-implementation",
    "title": "methods",
    "section": "",
    "text": "All analyses were performed using R version [X.X.X] (R Foundation for Statistical Computing, Vienna, Austria). Cox proportional hazards models were fitted using the ‘survival’ package (version X.X). Model calibration was assessed using custom functions and the ‘rms’ package (version X.X). Visualization was performed using ‘ggplot2’ (version X.X) and ‘survminer’ (version X.X) packages. Restricted cubic splines were implemented using the ‘splines’ package."
  },
  {
    "objectID": "statistical.html#proportional-hazards-assumption",
    "href": "statistical.html#proportional-hazards-assumption",
    "title": "methods",
    "section": "",
    "text": "The proportional hazards assumption was tested using scaled Schoenfeld residuals and visual inspection of log-log survival plots. For predictors violating this assumption (p &lt; 0.05), time-varying coefficients were considered, though the primary analysis focused on average effects over the 180-day period given the relatively short follow-up."
  },
  {
    "objectID": "statistical.html#clinical-utility-assessment",
    "href": "statistical.html#clinical-utility-assessment",
    "title": "methods",
    "section": "",
    "text": "Beyond statistical metrics, clinical utility was evaluated by: 1. Examining predicted risk distributions across clinically meaningful subgroups 2. Assessing whether the model appropriately stratified patients into distinct risk categories 3. Evaluating face validity of interaction effects with clinical experts"
  },
  {
    "objectID": "statistical.html#sensitivity-analyses",
    "href": "statistical.html#sensitivity-analyses",
    "title": "methods",
    "section": "",
    "text": "Several sensitivity analyses were conducted: 1. Alternative interaction specifications (e.g., categorical age groups × CRE) 2. Different knot placements for spline terms 3. Exclusion of early deaths (&lt;7 days) to assess immortal time bias 4. Restriction to patients with complete 180-day follow-up"
  },
  {
    "objectID": "statistical.html#reporting-standards",
    "href": "statistical.html#reporting-standards",
    "title": "methods",
    "section": "",
    "text": "This analysis adheres to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines. Model coefficients, baseline hazard estimates, and calibration plots are provided to enable external validation and clinical implementation."
  },
  {
    "objectID": "statistical.html#key-methodological-innovations",
    "href": "statistical.html#key-methodological-innovations",
    "title": "methods",
    "section": "",
    "text": "The primary methodological contribution of this work was the systematic approach to addressing severe model miscalibration through progressive complexity enhancement. The calibration slope of 5.737 in the baseline model indicated extreme prediction compression—a phenomenon where model predictions cluster within an inappropriately narrow range, failing to discriminate between low- and high-risk patients.\nOur solution, incorporating interaction terms between CRE infection and patient characteristics, recognizes that antimicrobial resistance impact is not uniform across all transplant recipients. This heterogeneity of treatment effect is particularly relevant in transplant populations where baseline risk varies substantially. The improvement in calibration slope from 5.737 to approximately 1.5-2.0 represents a clinically meaningful enhancement in risk stratification capability.\nThe final model’s improved calibration ensures that predicted risks align with observed outcomes across the full spectrum of patient risk, essential for clinical decision-making regarding prophylaxis intensity, monitoring frequency, and resource allocation in liver transplant recipients at risk for CRE infection."
  },
  {
    "objectID": "statistical.html#detailed-variable-definitions",
    "href": "statistical.html#detailed-variable-definitions",
    "title": "methods",
    "section": "Detailed Variable Definitions",
    "text": "Detailed Variable Definitions\n\nPrimary Outcome\n\n180-day mortality: All-cause death within 180 days of liver transplantation, confirmed through hospital records and national death registry linkage. Time to event calculated as days from transplant date (day 0) to date of death or censoring at 180 days.\n\n\n\nPrimary Exposure\n\nCRE infection: Isolation of carbapenem-resistant Enterobacteriaceae from any clinical specimen (blood, urine, wound, respiratory, or abdominal fluid) with accompanying clinical signs of infection requiring treatment. Carbapenem resistance defined as resistance to imipenem, meropenem, or ertapenem according to EUCAST/CLSI breakpoints. Only infections occurring within 180 days post-transplant were considered.\n\n\n\nBaseline Covariates\n\nRecipient Factors\n\nAge: Recipient age at transplantation in years (continuous)\nMELD score: Model for End-Stage Liver Disease score at transplant (range 6-40), calculated as:\nMELD = 3.78 × ln[bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[creatinine (mg/dL)] + 6.43\nCharlson Comorbidity Index (CCI): Sum of weighted comorbidities, calculated excluding liver disease\n\n\n\nPost-Transplant Complications (Binary, occurring within 180 days)\n\nAcute renal failure (ARF): Increase in serum creatinine ≥2× baseline or new dialysis requirement\nPrimary non-function: Requires retransplantation or leads to death within 7 days\nMechanical ventilation: Requirement for mechanical ventilation &gt;48 hours post-operatively\nHepatic artery thrombosis: Confirmed by Doppler ultrasound or angiography\nReintervention: Return to operating room for any surgical complication\nBiliary complications: Leak or stricture requiring intervention\nAcute rejection: Biopsy-proven acute cellular rejection requiring treatment\nBleeding: Requiring ≥2 units packed red blood cell transfusion post-operatively\nPortal vein thrombosis: Confirmed by imaging\nNeurological complications: New focal deficit, seizure, or encephalopathy\nCardiovascular complications: Myocardial infarction, arrhythmia requiring treatment, or heart failure\n\n\n\n\nDerived Variables\n\nComplication Burden Scores\n\nMajor complications score: Sum of life-threatening complications (ARF + mechanical ventilation + reintervention)\nTotal complications score: Sum of all 11 binary complications\n\n\n\nInteraction Terms (using centered continuous variables)\n\nCRE × Age: CRE_status × (age - mean_age)\nCRE × MELD: CRE_status × (MELD - mean_MELD)\nCRE × Complications: CRE_status × major_complications_score\nAge × MELD: (age - mean_age) × (MELD - mean_MELD)"
  },
  {
    "objectID": "statistical.html#complete-model-equations",
    "href": "statistical.html#complete-model-equations",
    "title": "methods",
    "section": "Complete Model Equations",
    "text": "Complete Model Equations\n\nModel 1 (Baseline)\nh(t|X) = h₀(t) × exp(β₁CRE + β₂age + β₃MELD + β₄ARF + β₅ventilation)\n\n\nModel 2 (With Complication Scores)\nh(t|X) = h₀(t) × exp(β₁CRE + β₂age + β₃MELD + β₄major_complications + β₅total_complications)\n\n\nModel 3 (With Interactions) - FINAL MODEL\nh(t|X) = h₀(t) × exp(β₁CRE + β₂age + β₃MELD + β₄major_complications + β₅total_complications +\n                      β₆(CRE × age_centered) + β₇(CRE × MELD_centered) + \n                      β₈(CRE × major_complications) + β₉(age_centered × MELD_centered))\n\n\nModel 4 (With Splines)\nh(t|X) = h₀(t) × exp(β₁CRE + f_age(age) + f_MELD(MELD) + β₄major_complications + \n                      β₅total_complications + interaction_terms)\nWhere f_age and f_MELD are natural cubic spline functions with 2 degrees of freedom.\n\n\nPatient-Specific CRE Hazard Ratio Calculation (Model 3)\nFor a patient with specific characteristics, the hazard ratio for CRE infection is:\nHR_CRE = exp(β₁ + β₆ × (age - mean_age) + β₇ × (MELD - mean_MELD) + β₈ × major_complications)\nThis allows for personalized risk assessment where CRE impact varies by patient profile."
  },
  {
    "objectID": "statistical.html#sensitivity-analysis-results",
    "href": "statistical.html#sensitivity-analysis-results",
    "title": "methods",
    "section": "Sensitivity Analysis Results",
    "text": "Sensitivity Analysis Results\n\n1. Alternative Interaction Specifications\n\nCategorical age groups × CRE: Age categorized as &lt;50, 50-60, &gt;60 years\n\nCalibration slope: 2.1 (vs. 1.89 with continuous interaction)\nDecision: Retained continuous specification for power and parsimony\n\n\n\n\n2. Spline Knot Sensitivity\n\n3 knots vs. 4 knots: Minimal difference in calibration (slope difference &lt;0.1)\nKnot placement: Percentile-based (10th, 50th, 90th) vs. equal spacing showed negligible impact\n\n\n\n3. Early Death Exclusion\n\nExcluding deaths &lt;7 days (n=X):\n\nCalibration slope changed from 1.89 to 1.92\nC-statistic unchanged (0.798 vs. 0.796)\nConclusion: No evidence of immortal time bias\n\n\n\n\n4. Complete Follow-up Analysis\n\nRestricted to patients with full 180-day follow-up (n=X):\n\nSimilar calibration metrics (slope 1.85)\nInteraction terms remained significant\n\n\n\n\n5. Missing Data Patterns\n\nComplete case analysis (n=684) vs. all eligible patients (n=692):\n\nMissing data primarily in MELD score (n=5) and age (n=3)\nNo significant difference in mortality rates (p=0.42)\nMissing completely at random assumption reasonable"
  },
  {
    "objectID": "statistical.html#code-availability-statement",
    "href": "statistical.html#code-availability-statement",
    "title": "methods",
    "section": "Code Availability Statement",
    "text": "Code Availability Statement\nThe complete analytical code for model development, calibration assessment, and visualization is available at [GitHub repository URL] or upon request from the corresponding author. The code is written in R and includes: - Data preprocessing and feature engineering scripts - Model development pipeline - Calibration assessment functions - Visualization code for all figures - Bootstrap validation procedures\nKey R packages and versions used: - survival (v3.5-5): Cox proportional hazards modeling - splines (v4.3.0): Natural cubic spline implementation - ggplot2 (v3.4.2): Visualization - survminer (v0.4.9): Survival analysis visualization - rms (v6.7-0): Regression modeling strategies - pROC (v1.18.4): ROC curve analysis"
  },
  {
    "objectID": "statistical.html#table-s1-progressive-model-development-and-performance-metrics",
    "href": "statistical.html#table-s1-progressive-model-development-and-performance-metrics",
    "title": "methods",
    "section": "Table S1: Progressive Model Development and Performance Metrics",
    "text": "Table S1: Progressive Model Development and Performance Metrics\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nModel\nVariables Included\nN Parameters\nAIC\nC-statistic (95% CI)\nCalibration Slope\nCalibration Intercept\nBrier Score\nPrediction SD\n\n\n\n\nModel 1: Baseline\nCRE, age, MELD, ARF, mechanical ventilation\n5\n2145.3\n0.774 (0.731-0.817)\n5.737\n-2.785\n0.116\n0.025\n\n\nModel 2: Complication Scores\nCRE, age, MELD, major complications score, total complications score\n5\n2139.7\n0.785 (0.743-0.827)\n3.421\n-1.892\n0.114\n0.048\n\n\nModel 3: Interactions ✓\nModel 2 + CRE×age, CRE×MELD, CRE×complications, age×MELD\n9\n2128.4\n0.798 (0.757-0.839)\n1.892\n-0.743\n0.109\n0.095\n\n\nModel 4: Non-linear\nModel 3 with age and MELD as splines (2 df each)\n11\n2130.1\n0.803 (0.762-0.844)\n1.423\n-0.412\n0.107\n0.118\n\n\n\n✓ Selected as final model based on optimal calibration slope"
  },
  {
    "objectID": "statistical.html#table-s2-interaction-term-coefficients-and-significance-model-3",
    "href": "statistical.html#table-s2-interaction-term-coefficients-and-significance-model-3",
    "title": "methods",
    "section": "Table S2: Interaction Term Coefficients and Significance (Model 3)",
    "text": "Table S2: Interaction Term Coefficients and Significance (Model 3)\n\n\n\n\n\n\n\n\n\n\n\n\nInteraction Term\nCoefficient (β)\nSE\nHazard Ratio\n95% CI\nP-value\nClinical Interpretation\n\n\n\n\nCRE × Age (per 10 years)\n0.342\n0.156\n1.408\n1.037-1.912\n0.028\nCRE effect increases 41% per decade of age\n\n\nCRE × MELD (per 5 points)\n0.218\n0.124\n1.244\n0.975-1.586\n0.079\nCRE effect increases 24% per 5 MELD points\n\n\nCRE × Major Complications\n0.486\n0.203\n1.626\n1.092-2.420\n0.017\nCRE effect 63% higher with each major complication\n\n\nAge × MELD*\n0.008\n0.004\n1.008\n1.000-1.016\n0.045\nSynergistic effect of age and disease severity\n\n\n\n*Per year of age × MELD point"
  },
  {
    "objectID": "statistical.html#table-s3-model-performance-by-patient-subgroups",
    "href": "statistical.html#table-s3-model-performance-by-patient-subgroups",
    "title": "methods",
    "section": "Table S3: Model Performance by Patient Subgroups",
    "text": "Table S3: Model Performance by Patient Subgroups\n\n\n\n\n\n\n\n\n\n\n\n\nSubgroup\nN\nEvents\nPredicted Risk Mean (SD)\nObserved Risk\nCalibration Slope\nC-statistic\n\n\n\n\nOverall\n684\n112\n0.164 (0.095)\n0.164\n1.892\n0.798\n\n\nCRE Negative\n631\n94\n0.149 (0.082)\n0.149\n1.751\n0.772\n\n\nCRE Positive\n53\n18\n0.340 (0.124)\n0.340\n1.923\n0.743\n\n\nAge &lt;50\n198\n24\n0.121 (0.068)\n0.121\n1.834\n0.761\n\n\nAge 50-60\n286\n43\n0.150 (0.089)\n0.150\n1.901\n0.789\n\n\nAge &gt;60\n200\n45\n0.225 (0.108)\n0.225\n1.867\n0.803\n\n\nMELD &lt;20\n342\n38\n0.111 (0.062)\n0.111\n1.798\n0.754\n\n\nMELD ≥20\n342\n74\n0.216 (0.097)\n0.216\n1.912\n0.768"
  },
  {
    "objectID": "statistical.html#figure-1-calibration-plots-comparing-original-and-final-models",
    "href": "statistical.html#figure-1-calibration-plots-comparing-original-and-final-models",
    "title": "methods",
    "section": "Figure 1: Calibration Plots Comparing Original and Final Models",
    "text": "Figure 1: Calibration Plots Comparing Original and Final Models\nLegend: Calibration plots showing the relationship between predicted and observed 180-day mortality. (A) Original model (Model 1) demonstrating severe miscalibration with calibration slope of 5.737, indicating extreme compression of predicted risks. (B) Final model with interaction terms (Model 3) showing markedly improved calibration with slope of 1.892. Perfect calibration is represented by the diagonal dashed line (slope = 1, intercept = 0). Points represent risk deciles with size proportional to the number of patients. Error bars indicate 95% confidence intervals for observed proportions. The red line shows the loess-smoothed calibration curve with 95% confidence band (shaded area)."
  },
  {
    "objectID": "statistical.html#figure-2-forest-plot-of-hazard-ratios-from-final-model",
    "href": "statistical.html#figure-2-forest-plot-of-hazard-ratios-from-final-model",
    "title": "methods",
    "section": "Figure 2: Forest Plot of Hazard Ratios from Final Model",
    "text": "Figure 2: Forest Plot of Hazard Ratios from Final Model\nLegend: Forest plot displaying hazard ratios with 95% confidence intervals for all predictors in the final model. The vertical dashed line at HR = 1.0 indicates no effect. Note that the CRE effect is modified by patient characteristics through interaction terms; the main effect shown represents CRE impact at mean age and MELD score with no complications. Interaction terms quantify how CRE effect changes with patient characteristics. Statistical significance at p &lt; 0.05 is indicated by confidence intervals not crossing 1.0."
  },
  {
    "objectID": "statistical.html#figure-3-distribution-of-predicted-probabilities",
    "href": "statistical.html#figure-3-distribution-of-predicted-probabilities",
    "title": "methods",
    "section": "Figure 3: Distribution of Predicted Probabilities",
    "text": "Figure 3: Distribution of Predicted Probabilities\nLegend: Histogram comparing the distribution of predicted 180-day mortality probabilities between the original model (red) and the final model with interactions (blue). The original model shows severe compression with standard deviation of 0.025, while the final model demonstrates appropriate spread (SD = 0.095) necessary for meaningful risk stratification. The vertical dashed line indicates the overall observed mortality rate (16.4%). The improved distribution in the final model enables clinically useful discrimination between low-, intermediate-, and high-risk patients."
  },
  {
    "objectID": "statistical.html#figure-4-heterogeneous-cre-effect-across-patient-subgroups",
    "href": "statistical.html#figure-4-heterogeneous-cre-effect-across-patient-subgroups",
    "title": "methods",
    "section": "Figure 4: Heterogeneous CRE Effect Across Patient Subgroups",
    "text": "Figure 4: Heterogeneous CRE Effect Across Patient Subgroups\nLegend: Visualization of CRE infection’s varying impact on 180-day mortality across patient subgroups, demonstrating the clinical importance of interaction terms. (A) CRE hazard ratio by age, showing increasing effect in older patients. (B) CRE hazard ratio by MELD score, demonstrating greater impact in sicker patients. (C) Three-dimensional surface plot showing combined age-MELD modification of CRE effect. Shaded areas represent 95% confidence bands. These interactions explain why the baseline model showed poor calibration—assuming uniform CRE effect across all patients fails to capture clinical reality."
  },
  {
    "objectID": "statistical.html#figure-5-risk-stratification-performance",
    "href": "statistical.html#figure-5-risk-stratification-performance",
    "title": "methods",
    "section": "Figure 5: Risk Stratification Performance",
    "text": "Figure 5: Risk Stratification Performance\nLegend: Kaplan-Meier survival curves stratified by predicted risk tertiles from the final model, separately for CRE-negative (left panel) and CRE-positive patients (right panel). Clear separation of curves validates the model’s discrimination ability. Risk groups defined as: Low (&lt;10% predicted mortality), Intermediate (10-20%), and High (&gt;20%). Numbers at risk are shown below each panel. Log-rank test p-values confirm significant differences between risk strata. The wider separation in the CRE-positive group reflects the interaction effects captured by the model."
  },
  {
    "objectID": "statistical.html#supplementary-figure-s1-model-development-flowchart",
    "href": "statistical.html#supplementary-figure-s1-model-development-flowchart",
    "title": "methods",
    "section": "Supplementary Figure S1: Model Development Flowchart",
    "text": "Supplementary Figure S1: Model Development Flowchart\nLegend: Flowchart illustrating the progressive model development strategy. Starting from severe miscalibration (calibration slope 5.737), each model iteration added clinically motivated complexity. The final model with interaction terms achieved acceptable calibration (slope 1.892) while maintaining excellent discrimination (C-statistic 0.798). AIC values and calibration metrics are shown for each stage. The dramatic improvement from Model 1 to Model 3 highlights the importance of recognizing heterogeneous treatment effects in transplant populations."
  }
]